judging from the share price. market not really treat kanger as a vaccine ctr. then why you all keep posting big vaccine articles and blocking tiny bamboo articles. who is going to repost all the bamboo articles if more and more are posting big vaccine articles occupy the whole forum front page. big vaccine articles also cannot move kanger price at all. correct?
I think lots of speculators who missed the vaccine boat bought in heaps of Kanger in the hope that making that kill, not knowing head or tail but depended on the rumours filled by other speculators who moved in much earlier. In a dog eat dog world, those caught at the most unfortunate end live on that last shred of hope - and when others point out what is at stake, verbal fights take place. The trick to investment is to do research properly. Then you dont have to worry about bad news purportedly created by others because you already know what you are in. It's like buying your first house - or car - you check and check until you are happy. If you dont, you have only yourself to curse if you bought a lemon instead of a tangerine
“For a start, we will be establishing a mobile sales and marketing team to approach the private clinics throughout Malaysia,” K-Star’s executive chairman Ding Jianping pointed out.
According to Ding, a key person who will be spearheading this initiative is K-Star’s executive director Koo Kien Yoon who was the executive director of Biosis Group Bhd for three years in 2013 to 2016 where he spearheaded the sales, marketing and distribution of healthcare and pharmaceutical products for Biosis.
“With his established business network as well as personal experience in the industry, K-Star would be able to leverage Koo’s prior experience and knowledge to establish a leading market position in this business of distributing COVID-19 vaccines to private clinics in Malaysia,” noted Ding.
kstar create news when sign agreement with ksnger to goreng the ctr to almost rm1 lah. now left 20sen. look at their company performance. market vaccine from new comer talk easy lah. kstar loss making ctr lah. got reputation kah? correct?
kanger real income will be from bamboo business. usd100bil real market waiting out there lah. yet you all talk vaccine so much. dont block bamboo articles lah. correct?
@UlarSawa Not saying the company's performance is good but i think the reason why Kanger collaborated with Kstar is because both also HQ in China. Kanger could be favouring China based company..
Well..we have another 2 weeks before end of December to know where we are heading. Prices seemed bottomed out between 170 to 175 for weeks. I am not worried at all.
Sharks playing waiting game. I already bought and paid for. Not adding or selling. Just dormant. In fact these days, pun tak larat to open my trading account to see Kanger price.
This company is raising RM through private placement just show this company is in a very poor financial health. This counter trap investors and kept them in with its sinopharm hope.
@Bigbladd Not everyone here is "trapped". I bought at a relatively lower price plus i am using my spare cash here. I can leave whenever i want to but i choose not to leave for now. I will hold for as long as i want to see how far it can go or not go...
Sinopharm’s vaccines are both made from coronaviruses that have been killed or weakened, a technique that has been used for decades in the influenza and polio vaccines, for example. By comparison, Moderna’s and Pfizer’s vaccines use a technology that has never before been approved for widespread use.
Another advantage of the inactivated vaccines being developed by Sinopharm is that they tend to have fewer adverse effects after immunization, according to Florian Krammer, an immunologist at the Icahn School of Medicine at Mount Sinai in New York. He said more clarity on the trials in the Emirates would be welcome, but expressed confidence in the vaccine’s initial results.
half day flooded the forum with vaccine articles. share price also not move. why wasting the forum front page with unproductive advertisement. correct?
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
UlarSawa
35,552 posts
Posted by UlarSawa > 2020-12-10 09:57 | Report Abuse
judging from the share price. market not really treat kanger as a vaccine ctr. then why you all keep posting big vaccine articles and blocking tiny bamboo articles. who is going to repost all the bamboo articles if more and more are posting big vaccine articles occupy the whole forum front page. big vaccine articles also cannot move kanger price at all. correct?